Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial

2016 ASCO Annual Meeting
Tweet this page

Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion (Abstract LBA2000).

Advertisement

Advertisement

Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.